GH

Guardant Health Inc

Guardant Health, Inc. is a precision oncology company, which engages in provision of precision oncology testing and development services. It focuses performing blood tests, vast data sets, and advanced analytics to conquer cancer. The company was founded by Helmy Eltoukhy and AmirAli H. Talasaz in 2012 and is headquartered in Redwood City, CA.

Guardant Health Inc (GH) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B-); its weakest is Profitability (D+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
B-
Factor Score 3.0 / 5.0
Profitability
D+
Factor Score 1.7 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C-
Factor Score 1.9 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.0
EV / EBITDA -5.4
Rev Growth YoY 44.3%
Gross Margin 65.0%
Price Return 3M 75.3%
Price Return 12M 285.8%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales 18.1
ROE N/M

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-08-05 C+ (2.5) B- (3.0) D+ (1.7) C (2.4) C- (1.9) C (2.3)
2026-08-04 C+ (2.5) B- (3.0) D+ (1.7) C (2.4) C- (1.9) C (2.3)
2026-08-03 C+ (2.5) C+ (2.6) C (2.2) C (2.4) C- (2.0) C (2.3)
2026-08-02 C+ (2.5) C+ (2.6) C (2.2) C (2.4) C- (1.9) C (2.3)
2024-03-31 C+ (2.6) B+ (3.5) C+ (2.7) A (4.2) D+ (1.5) B- (2.9)
Page 1 of 4